Korean Journal of Veterinary Service (한국동물위생학회지)

The Korean Society of Veterinary Service (한국동물위생학회)
권호 표지
DOI QR코드

DOI QR Code

Toceranib therapy for hepatic fibrosarcoma in a dog

  • Mi Kyung Park (College of Veterinary Medicine, Chungnam National University) ;
  • Kun Ho Song (College of Veterinary Medicine, Chungnam National University)
  • Received : 2023.06.02
  • Accepted : 2023.07.30
  • Published : 2023.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

A 12-year-old neutered male Maltese was brought to our hospital with loss of appetite, generalized alopecia, anemia, and a palpable abdominal mass. Ultrasonography revealed multiple abdominal masses in the liver and spleen. Subsequently, splenectomy and liver biopsy were performed, and the masses were histologically diagnosed as metastatic fibrosarcomas of unknown primary origin. The owner refused further investigations such as computed tomography and hepatectomy, therefore, we decided to initiate chemotherapy in the form of metronomic therapy with toceranib phosphate, which has several advantages, such as better tolerability, low cost, and convenience. The size and number of hepatic fibrosarcomas continued to increase despite continued administration of toceranib (10 mg/dog, PO, q48h). The dog died approximately 43 days after initiation of the toceranib treatment. To the best of our knowledge, this is the first report on toceranib therapy for metastatic hepatic fibrosarcoma in a dog.

Keywords

References

  1. Calvalido J, Wood GA, Mutsaers AJ, Wood D, Sears W, Woods JP. 2016. Comparison of serum cytokine levels between dogs with multicentric lymphoma and healthy dogs. Vet Immunol Immunopathol 182: 106-114. https://doi.org/10.1016/j.vetimm.2016.10.009
  2. Carmeliet P. 2005. VEGF as a key mediator of angiogenesis in cancer. Oncology 69: 4-10. https://doi.org/10.1159/000088478
  3. Day MJ, Lucke VM, Pearson H. 1995. A review of pathological diagnoses made from 87 canine splenic biopsies. J Small Anim Pract 36: 426-433. https://doi.org/10.1111/j.1748-5827.1995.tb02769.x
  4. Frezoulis P, Harper A. 2022. The role of toceranib phosphate in dogs with non-mast cell neoplasia: A systematic review. Vet Comp Oncol 20: 362-371. https://doi.org/10.1111/vco.12799
  5. Gardner HL, London CA, Portela RA, Nguyen S, Rosenberg MP, Klein MK, Clifford C, Thamm DH, Vail DM, Bergman P, Crawford-Jakubiak M, Henry C, Locke J, Garrett LD. 2015. Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma. Vet Res 11: 131.
  6. Goldschmidt MH, Hendrick MJ. 2002. Tumors of the skin and soft tissues, pp. 45-117. In: Meuten DJ (ed.). Tumors in domestic animals. 4th ed. Iowa State University Press. Iowa.
  7. Hisada Y, Mackman N. 2019. Tissue factor and cancer: regulation, tumor growth, and metastasis. Semin Thromb Hemost 45: 385-395. https://doi.org/10.1055/s-0039-1687894
  8. Jang JK, Chretin J, Bruyette D, Hu P, Epstein AL. 2015. Phase 1 dose-escalation study with LEC/chTNT-3 and toceranib phosphate (Palladia®) in dogs with spontaneous malignancies. J Cancer Sci Ther 7: 167-174. https://doi.org/10.4172/1948-5956.1000343
  9. Kim KT, Han SY, Park EH, Jang JS, Roh MH, Lee SW, Jeong JS. 2007. A case of the treatment in an adult with hepatic undifferentiated (embryonal) sarcoma. Korean J Hepatol 13: 96-102.
  10. Laver T, London CA, Vail DM, Biller BJ, Coy J, Thamm DH. 2018. Prospective evaluation of toceranib phosphate in metastatic canine osteosarcoma. Vet Comp Oncol 16: E23-E29. https://doi.org/10.1111/vco.12328
  11. Milovancev M, Helfand SC, Marley K, Goodall CP, Lohr CV, Bracha S. 2016. Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro. Vet Res 12:85.
  12. Mitchell L, Thamm DH, Biller BJ. 2012. Clinical and immunomodulatory effects of Toceranib combined with low-dose cyclophosphamide in dogs with cancer. J Vet Intern Med 26: 355-362. https://doi.org/10.1111/j.1939-1676.2011.00883.x
  13. Nguyen SM, Thamm DH, Vail DM, London CA. 2015. Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document. Vet Comp Oncol 13: 176-183. https://doi.org/10.1111/vco.12032
  14. Pan X, Tsimbas K, Kurzman ID, Vail DM. 2016. Safety evaluation of combination CCNU and continuous toceranib phosphate (Palladia®) in tumour-bearing dogs: a phase I dose-finding study. Vet Comp Oncol 14: 202-209. https://doi.org/10.1111/vco.12091
  15. Patnaik AK, Hurvitz AI, Lieberman PH. 1980. Canine hepatic neoplasms: a clinicopathologic study. Vet pathol 17: 553-564. https://doi.org/10.1177/030098588001700504
  16. Spangler WL, Culbertson MR, Kass PH. 1994. Primary mesenchymal (nonangiomatous/nonlymphomatous) neoplasms occurring in the canine spleen: anatomic classification, immunohistochemistry, and mitotic activity correlated with patient survival. Vet Pathol 31: 37-47. https://doi.org/10.1177/030098589403100105